Durham, NC, June 16, 2022 – BioAgilytix Labs, LLC (“BioAgilytix”), a leading global contract research organization focused on supporting pharmaceutical and biotech partners in all phases of drug development, today…
Durham, NC, June 30, 2022 – BioAgilytix Labs, LLC (BioAgilytix), a leading global contract research organization focused on supporting pharmaceutical and biotech partners in all phases of drug development, has appointed…
Durham, NC, June 23, 2022 – BioAgilytix Labs, LLC (BioAgilytix), a leading global contract research organization focused on supporting pharmaceutical and biotech partners in all phases of drug development, has…
Durham, NC, May 9, 2022 – BioAgilytix Labs, LLC (BioAgilytix), a leading global contract research organization focused on supporting pharmaceutical and biotech partners in all phases of drug development, has…
Durham, NC, May 4, 2022 – BioAgilytix Labs, LLC (BioAgilytix), a leading global contract research organization focused on supporting pharmaceutical and biotech partners in all phases of drug development, has appointed two…
Investment will Power Further Expansion of Core Business and Drive Future Growth of the Company December 21, 2021—Durham, NC, USA and London, UK—BioAgilytix, a leading global contract research organization (CRO),…
Investment Will Provide BioAgilytix with Additional Resources to Invest in Core Business and Drive GrowthNovember 17, 2021—Durham, NC, USA, Brussels, Belgium and London, UK—BioAgilytix, a leading global contract research organization…
Following final government approval, 360biolabs, a BioAgilytix company, adds world-class virology & immunology expertise and LC/MS/MS small molecule capabilities to the company, enabling support of bioanalytical services across all geographies…
Alliance to strengthen both companies’ ability to provide a seamless, full-service bioanalytical client experience across the full spectrum of lifecycle developmentDurham, NC, October 4, 2021 – BioAgilytix Labs, LLC (BioAgilytix), a leading…